Experts and Doctors on micrornas in Catanzaro, Calabria, Italy

Summary

Locale: Catanzaro, Calabria, Italy
Topic: micrornas

Top Publications

  1. Colangelo T, Polcaro G, Ziccardi P, Pucci B, Muccillo L, Galgani M, et al. Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer. Cell Death Dis. 2016;7:e2120 pubmed publisher
    ..These results may pave the way for better diagnosis, patient stratification and novel therapeutic approaches. ..
  2. Tagliaferri P, Rossi M, Di Martino M, Amodio N, Leone E, Gulla A, et al. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets. 2012;12:838-46 pubmed
  3. Di Martino M, Leone E, Amodio N, Foresta U, Lionetti M, Pitari M, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012;18:6260-70 pubmed publisher
    ..Our findings provide a proof-of-principle that formulated synthetic miR-34a has therapeutic activity in preclinical models and support a framework for development of miR-34a-based treatment strategies in MM patients. ..
  4. Iaconetti C, Sorrentino S, De Rosa S, Indolfi C. Exosomal miRNAs in Heart Disease. Physiology (Bethesda). 2016;31:16-24 pubmed publisher
    ..This review addresses the functional role played by exosomal miRNAs in heart disease and their potential use as new biomarkers. ..
  5. Cristiano F, Veltri P. Methods and Techniques for miRNA Data Analysis. Methods Mol Biol. 2016;1375:11-23 pubmed publisher
    ..In this chapter we present an overview of available software platforms for genomic data analysis, as well as available databases with their query engines. ..
  6. Rossi M, Amodio N, Di Martino M, Caracciolo D, Tagliaferri P, Tassone P. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets. 2013;14:1144-9 pubmed
    ..Finally, a detailed overview of the recent findings on miRNA therapeutics of MM will be discussed. ..
  7. Di Martino M, Gullà A, Cantafio M, Lionetti M, Leone E, Amodio N, et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget. 2013;4:242-55 pubmed
    ..These findings suggest that MM genotyping may predict the therapeutic response. All together our results support a framework for clinical development of miR-221/222 inhibitors-based therapeutic strategy in this still incurable disease. ..
  8. Gareri C, Iaconetti C, Sorrentino S, Covello C, de Rosa S, Indolfi C. miR-125a-5p Modulates Phenotypic Switch of Vascular Smooth Muscle Cells by Targeting ETS-1. J Mol Biol. 2017;429:1817-1828 pubmed publisher
    ..Thus, miR-125a-5p in this context inhibits PDGF-BB pathway and is therefore a potential regulator of VSMCs phenotypic switch. ..
  9. Fulciniti M, Amodio N, Bandi R, Cagnetta A, Samur M, Acharya C, et al. miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J. 2016;6:e380 pubmed publisher
    ..Thus MYC-dependent miR-23b repression in myeloma cells may promote activation of oncogenic Sp1-mediated signaling, representing the first feed-forward loop with critical growth and survival role in myeloma. ..

More Information

Publications20

  1. Matà R, Palladino C, Nicolosi M, Lo Presti A, Malaguarnera R, Ragusa M, et al. IGF-I induces upregulation of DDR1 collagen receptor in breast cancer cells by suppressing MIR-199a-5p through the PI3K/AKT pathway. Oncotarget. 2016;7:7683-700 pubmed publisher
    ..Therefore, this signaling pathway may represent an important target for breast cancers with over-activation of the IGF-IR axis. ..
  2. Gullà A, Di Martino M, Gallo Cantafio M, Morelli E, Amodio N, Botta C, et al. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res. 2016;22:1222-33 pubmed publisher
  3. Curcio A, Torella D, Iaconetti C, Pasceri E, Sabatino J, Sorrentino S, et al. MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. PLoS ONE. 2013;8:e70158 pubmed publisher
    ..Treatment of pressure overload-induced myocyte hypertrophy reduces the risk of life-threatening VT by normalizing miR-1 expression levels with the consequent stabilization of Cx43 expression and activity within the gap junction. ..
  4. Fiume G, Rossi A, Di Salle E, Spatuzza C, Mallardo M, Scala G, et al. Computational analysis and in vivo validation of a microRNA encoded by the IBTK gene, a regulator of B-lymphocytes differentiation and survival. Comput Biol Chem. 2009;33:434-9 pubmed publisher
    ..By CLUSTALW-based analysis, pre-miR-IBTK3 homologues were found in Pan troglodytes, Pongo pygmaeus and Macaca mulatta, suggesting an evolutionary conserved function in primates. ..
  5. Leone E, Morelli E, Di Martino M, Amodio N, Foresta U, Gullà A, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013;19:2096-106 pubmed publisher
    ..Our findings show the first evidence that in vivo antagonism of miR-21 exerts anti-multiple myeloma activity, providing the rationale for clinical development of miR-21 inhibitors in this still incurable disease. ..
  6. Rossi M, Pitari M, Amodio N, Di Martino M, Conforti F, Leone E, et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol. 2013;228:1506-15 pubmed publisher
    ..Overall, these data indicate that enforced expression of miR-29b impairs OCL differentiation and overcomes OCL activation triggered by MM cells, providing a rationale for miR-29b-based treatment of MM-related BD. ..
  7. Amodio N, Di Martino M, Foresta U, Leone E, Lionetti M, Leotta M, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Dis. 2012;3:e436 pubmed publisher
    ..Our findings indicate that miR-29b is involved in a regulatory loop amenable of pharmacologic intervention and modulates the anti-MM activity of bortezomib in MM cells. ..
  8. Amodio N, Leotta M, Bellizzi D, Di Martino M, D Aquila P, Lionetti M, et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget. 2012;3:1246-58 pubmed
  9. Iaconetti C, Polimeni A, Sorrentino S, Sabatino J, Pironti G, Esposito G, et al. Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury. Basic Res Cardiol. 2012;107:296 pubmed publisher
    ..These data provide the first evidence that inhibition of miR-92a may represent a novel strategy to improve endothelial regeneration and reduce restenosis after vascular injury. ..
  10. Paduano F, Dattilo V, Narciso D, Bilotta A, Gaudio E, Menniti M, et al. Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328. FEBS J. 2013;280:401-12 pubmed publisher
  11. Torella D, Iaconetti C, Catalucci D, Ellison G, Leone A, Waring C, et al. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo. Circ Res. 2011;109:880-93 pubmed publisher
    ..Our data show that miR-133 is a key regulator of vascular smooth muscle cell phenotypic switch in vitro and in vivo, suggesting its potential therapeutic application for vascular diseases. ..